Hite Biopharma

Wuhan Hite Biopharmaceutical Co., Ltd. was founded on April 8, 1992. It is a high-tech biopharmaceutical enterprise in Hubei Province with the national Class I new drug "Jinlujie"—mouse nerve growth factor for injection—as its leading product, aiming to build a first-class innovative biopharmaceutical enterprise. The company has a registered capital of 103.35504 million yuan, and its registered address is Hite Science and Technology Park, Wuhan Economic and Technological Development Zone. Its main business is the research and development, production, and sales of biological products (mouse nerve growth factor for injection lyophilized powder for injection, anti-hepatitis B transfer factor for injection lyophilized powder for injection), thrombin, and other chemical drugs. On August 8, 2017, Wuhan Hite Biopharmaceutical Co., Ltd. (abbreviation: Hite Biopharma, stock code: 300683) held a bell-ringing listing ceremony at the Shenzhen Stock Exchange, officially landing on the ChiNext board for listing and trading, and entering the capital market. The factory covers an area of 138,000 square meters, with existing building area of more than 30,000 square meters, including more than 10,000 square meters of production workshops that meet national GMP certification standards. The company possesses more than 900 sets of production, research and development, and testing equipment, including imported protein chromatography separation systems, high-speed centrifuges, high-speed washing, drying, and filling production lines, large pharmaceutical vacuum freeze dryers, high-speed capping machines, laser inkjet printers, fermentation tanks, high-pressure homogenizers, fully automatic chromatography columns, high-performance liquid chromatography systems, gas chromatography systems, high-speed refrigerated centrifuges, carbon dioxide shakers, vacuum filling and stoppering machines for prefilled syringes, constant temperature and humidity chambers, etc.
The company has a relatively high level of management and strong talent advantages. The company operates in accordance with the standards of a listed company, implements a general manager responsibility system under the leadership of the board of directors, adopts a modern enterprise management model, and strictly conducts pharmaceutical production and comprehensive quality management in accordance with GMP requirements. The company currently has about 280 employees, bringing together a group of high-quality management talents and engineering technical personnel in China, among whom those with professional technical titles account for 34.4%, and those with a college degree or above account for 83%.
The company has unique product advantages. The leading product "Jinlujie"—mouse nerve growth factor for injection—is a national Class I new biological product and is the world's * first government-approved medication for neurological injury diseases to be listed. This project originated from the achievements of the 1986 Nobel Prize in Physiology or Medicine. The company successfully transformed it into an industrialized product and received key support from the National Torch Program and the National Innovation Fund Program. The company also has more than 20 products, including the hepatitis B treatment drug Aoganpei and the hemostatic agent thrombin.
The company holds a GMP certificate issued by the National Medical Products Administration and a drug production license issued by the Hubei Provincial Medical Products Administration. The company has 11 products, 6 authorized patents, 6 new drug certificates, and more than 40 trademarks.
The company has explored an overall strategy suitable for sustainable development in the field of biopharmaceuticals. The company's development strategy for the next three years remains positioned in the biopharmaceutical field, continuing to deepen its efforts, striving to become a first-class biological product supplier as soon as possible, and continuing to advance the overall strategic layout of the large health industry.